More males get, and die of, the deadly brain cancer glioblastoma than females. A team of researchers has identified distinct molecular signatures of glioblastoma in men and women that help explain disparities in patients' response to treatment and survival. The research suggests that tailoring treatments to men and women with glioblastoma based on the molecular subtypes of their tumors may improve survival for all patients.